Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RYTM Rhythm Pharmaceuticals Inc.

Not Yet Opened 10-16 16:00:00 EDT

86.17

-1.80

-2.05%

盘后85.00

-1.17-1.36%

19:30 EDT

High88.62	Low85.91	Vol367.04K
Open88.20	D1 Closing87.97	Amplitude3.08%
Mkt Cap5.93B	Tradable Cap5.64B	Total Shares68.85M
T/O31.91M	T/O Rate0.56%	Tradable Shares65.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RYTM","market":"US","secType":"STK","nameCN":"Rhythm Pharmaceuticals Inc.","latestPrice":86.17,"timestamp":1792180800000,"preClose":87.97,"halted":0,"volume":367036,"hourTrading":{"tag":"盘后","latestPrice":85,"preClose":86.17,"latestTime":"19:30 EDT","volume":22786,"amount":1962273.9384,"timestamp":1792193405367,"change":-1.17,"changeRate":-0.013578,"amplitude":0.013578},"delay":0,"changeRate":-0.020461520973058964,"floatShares":65394076,"shares":68852082,"eps":-3.117162,"marketStatus":"Not Yet Opened","change":-1.8,"latestTime":"10-16 16:00:00 EDT","open":88.2,"high":88.62,"low":85.91,"amount":31912737.81776,"amplitude":0.030806,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.117162,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1792396800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1507176000000,"exchange":"NASDAQ","adjPreClose":87.97,"preHourTrading":{"tag":"盘前","latestPrice":87.95,"preClose":87.97,"latestTime":"09:13 EDT","volume":112,"amount":9860.92016,"timestamp":1792156416282,"change":-0.02,"changeRate":-0.000227,"amplitude":0.011595},"postHourTrading":{"tag":"盘后","latestPrice":85,"preClose":86.17,"latestTime":"19:30 EDT","volume":22786,"amount":1962273.9384,"timestamp":1792193405367,"change":-1.17,"changeRate":-0.013578,"amplitude":0.013578},"volumeRatio":0.4818284476340621,"impliedVol":0.4069,"impliedVolPercentile":0.1235},"requestUrl":"/m/hq/s/RYTM","defaultTab":"news","newsList":[{"id":"2675545925","title":"Rhythm Pharmaceuticals initiated with an Outperform at William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2675545925","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675545925?lang=en_us&edition=fundamental","pubTime":"2026-10-16 09:05","pubTimestamp":1792112711,"startTime":"0","endTime":"0","summary":"William Blair analyst Alethia Young initiated coverage of Rhythm Pharmaceuticals (RYTM) with an Outperform rating. Rhythm is a global, commercial-s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-initiated-with-an-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-initiated-with-an-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","MEDI","BK4139","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675185314","title":"Rhythm Pharmaceuticals Launches Hypothalamic Obesity Treatment in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2675185314","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675185314?lang=en_us&edition=fundamental","pubTime":"2026-10-14 16:32","pubTimestamp":1791966766,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) launched Imcivree in Japan for the treatment of acquired hypothalamic obesity, the company said late Tuesday.Hypothalamic obesity is a rare, serious condition that can result in weight gain and uncontrollable hunger.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","RYTM","BK4588","BK4139","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675937393","title":"Rhythm Pharmaceuticals Announces Commercial Launch of Imcivree® (Setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2675937393","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675937393?lang=en_us&edition=fundamental","pubTime":"2026-10-14 07:30","pubTimestamp":1791934200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nTUA4QNWTK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","RYTM","BK4588","BK4139","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675238775","title":"Did Prader Willi Therapy Progress Just Shift Rhythm Pharmaceuticals' (RYTM) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2675238775","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675238775?lang=en_us&edition=fundamental","pubTime":"2026-10-13 11:37","pubTimestamp":1791862628,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals has seen sentiment improve after recent developments in Prader-Willi syndrome care, including clinical and regulatory progress around its targeted therapy setmelanotide and broader investment into this treatment area.\nThe key shift is that Prader-Willi syndrome is receiving more focused drug development and funding, which directly supports Rhythm Pharmaceuticals' core rare disease franchise and its effort to reach more genetically defined obesity patients.\nAttention...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/did-prader-willi-therapy-progress-just-shift-rhythm-pharmace","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/did-prader-willi-therapy-progress-just-shift-rhythm-pharmace","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MEDI","RYTM","BK4588","LU2065732104.USD","PRGS","BK4139","BK4097","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674711818","title":"Rhythm Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2674711818","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674711818?lang=en_us&edition=fundamental","pubTime":"2026-10-12 18:44","pubTimestamp":1791801840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","BK4585","BK4139","BK4588","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674871660","title":"Rhythm Pharmaceuticals (RYTM) Receives a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2674871660","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674871660?lang=en_us&edition=fundamental","pubTime":"2026-10-12 18:35","pubTimestamp":1791801350,"startTime":"0","endTime":"0","summary":"In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rhythm Pharmaceuticals, with a price target of $130.00. A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rhythm-pharmaceuticals-rytm-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rhythm-pharmaceuticals-rytm-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","RYTM","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674593879","title":"Rhythm Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $130 from $105","url":"https://stock-news.laohu8.com/highlight/detail?id=2674593879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674593879?lang=en_us&edition=fundamental","pubTime":"2026-10-12 18:12","pubTimestamp":1791799920,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nAZN4TOEKY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4139","MEDI","RYTM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674555938","title":"Rhythm Pharmaceuticals price target raised to $150 from $149 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2674555938","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674555938?lang=en_us&edition=fundamental","pubTime":"2026-10-09 18:35","pubTimestamp":1791542112,"startTime":"0","endTime":"0","summary":"BofA raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $150 from $149 and keeps a Buy rating on the shares. The firm rolled the qu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-price-target-raised-to-150-from-149-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-price-target-raised-to-150-from-149-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","BK4585","BK4139","RYTM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673006636","title":"Rhythm's Imcivree Launch in Hypothalamic Obesity Encouraging, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2673006636","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673006636?lang=en_us&edition=fundamental","pubTime":"2026-10-08 23:15","pubTimestamp":1791472549,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals'  early Imcivree feedback from four pediatric endocrinologists managing hypothalamic obesity patients is encouraging, RBC said in a note Thursday.RBC analysts said they spoke with the four key opinion leaders, who collectively have over 40 hypothalamic obesity patients, to assess the early launch of Imcivree.\"Our conversations were constructively encouraging,\" the report said, adding that three of the four KOLs already have patients on Imcivree and three also expect to increase their use of the drug.All four viewed Imcivree favorably, the report said.Based on the feedback, RBC analysts raised their estimated peak HO penetration to 20% from 15% and peak sales estimate to $1.5 billion from $1.3 billion.RBC raised its price target to $159 from $155 and reiterated its outperform rating with speculative risk.Price: 87.97, Change: -0.48, Percent Change: -0.54","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MEDI","BK4585","BK4588","RYTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673133072","title":"Analysts’ Top Healthcare Picks: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673133072","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673133072?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:10","pubTimestamp":1791461430,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD) and Rhythm Pharmaceuticals (R...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-gilead-sciences-gild-rhythm-pharmaceuticals-rytm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-gilead-sciences-gild-rhythm-pharmaceuticals-rytm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","LU0823416689.USD","LU2112291526.USD","LU1934455277.USD","LU0965509101.SGD","LU2324357040.USD","LU1674673428.USD","IE00B19Z3B42.SGD","SG9999015978.USD","SG9999015986.USD","IBBQ","LU0029874061.USD","LU2468319806.SGD","IE00BZ1G4Q59.USD","LU1934455863.HKD","BK4566","LU0058720904.USD","IE00B19Z3581.USD","LU0965508806.USD","LABU","LU0965509283.SGD","BK4137","LU0882574055.USD","BK4532","LU2357627491.SGD","TBXU","LU1066053197.SGD","XBI","XLV","LU1023059063.AUD","BMED","RYTM","LU2089984988.USD","GILD","BK4585","LU1037948897.HKD","LU0965509010.AUD","MEDI","BK4568","HCSG","TMED","LU0234570918.USD","BIB","BK4583","IE00B3T34201.USD","LU1934455194.USD","BBH","IE00B7SZLL34.SGD","LU0320765992.SGD","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673743070","title":"RBC Lifts Price Target on Rhythm Pharmaceuticals to $159 From $155, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2673743070","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673743070?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:46","pubTimestamp":1791460003,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) has an average rating of buy and mean price target of $147.71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","BK4139","RYTM","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673756090","title":"Rhythm Pharmaceuticals, Inc. : RBC Raises Target Price to $159 from $155","url":"https://stock-news.laohu8.com/highlight/detail?id=2673756090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673756090?lang=en_us&edition=fundamental","pubTime":"2026-10-08 18:13","pubTimestamp":1791454428,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45U11S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","BK4588","RYTM","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669414511","title":"Health Canada Approves Rhythm Pharma’s Imcivree for Acquired Hypothalamic Obesity Weight Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2669414511","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669414511?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:03","pubTimestamp":1790078594,"startTime":"0","endTime":"0","summary":"Health Canada approves Rhythm Pharma’s IMCIVREE for acquired hypothalamic obesity weight managementHealth Canada cleared Rhythm Pharmaceuticals’ IMCIVREE (setmelanotide) for weight management in acqui","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL5LrnfX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","BK4112","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014021.USD","IE00BQXX3D17.EUR","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014013.SGD","LU0314104364.USD","IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","RYTM","IE00BGHQF748.EUR","BK4588","NDAQ","BK4585","IE00BKPKM429.USD","BK4139","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141601","title":"Rhythm Pharmaceuticals Announces Health Canada Approval of Imcivree® (Setmelanotide) for Weight Management in Adult and Pediatric Patients 4 Years of Age and Older with Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141601","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141601?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078404,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA3C2WMX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDI","RYTM","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668867962","title":"Wolfe Research Initiates Rhythm Pharmaceuticals at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2668867962","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668867962?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:17","pubTimestamp":1789647463,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) has an average rating of buy and mean price target of $138.59, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RYTM","BK4139","BK4588","BK4585","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668596131","title":"Rhythm Pharmaceuticals initiated with an Outperform at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2668596131","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668596131?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:20","pubTimestamp":1789644024,"startTime":"0","endTime":"0","summary":"Wolfe Research analyst Kalpit Patel initiated coverage of Rhythm Pharmaceuticals (RYTM) with an Outperform rating. Published first on TheFly – the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-initiated-with-an-outperform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-initiated-with-an-outperform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","RYTM","MEDI","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667600751","title":"S&P 500 Futures Climb in Premarket Trading; Brookfield Infrastructure, Avnet Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=2667600751","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667600751?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:30","pubTimestamp":1789558200,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, Brookfield Infrastructure Partners L.P. (BIP) was up ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGUS","UXAP","DSPY","GPIX","GBXB","LGH","SPYM","XXX","FLAO","XPAY","CFO","RYTM","ISSXF","UOCT","VOOG","BKLC",".SPX","DBB","PTLC","PTL","TOPC","VOOX","HJUN","FELC","AVT","MRCP","VOO","FLCC","SPDF","VUG","TSPA","UXJA","XSPI","SSS","OALC","LGDX","XUSP","SPY","UXJL","CPST","FEBT","FTS","VYM","PBJL","ACLC","HELO","SCHG","ABIG","VSL","GSUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667905816","title":"RBC Capital Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667905816","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667905816?lang=en_us&edition=fundamental","pubTime":"2026-09-15 09:46","pubTimestamp":1789436789,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Lisa Walter maintained a Buy rating on Rhythm Pharmaceuticals yesterday and set a price target of $155.00. According to TipRank...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-rhythm-pharmaceuticals-rytm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-rhythm-pharmaceuticals-rytm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667345696","title":"Rhythm Pharmaceuticals Coverage Assumed by Leerink Partners at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2667345696","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667345696?lang=en_us&edition=fundamental","pubTime":"2026-09-15 05:09","pubTimestamp":1789420140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MEDI","BK4139","RYTM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667662220","title":"Rhythm Pharmaceuticals assumed with an Outperform at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2667662220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667662220?lang=en_us&edition=fundamental","pubTime":"2026-09-14 23:20","pubTimestamp":1789399249,"startTime":"0","endTime":"0","summary":"Leerink assumed coverage of Rhythm Pharmaceuticals (RYTM) with an Outperform rating and $133 price target Rhythm is emerging as a leader in rare ob...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-assumed-with-an-outperform-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-assumed-with-an-outperform-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RYTM","BK4139","BK4585","BK4588","MEDI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rhythmtx.com","stockEarnings":[{"period":"1week","weight":-0.0508},{"period":"1month","weight":-0.1208},{"period":"3month","weight":-0.1917},{"period":"6month","weight":-0.0284},{"period":"1year","weight":-0.225},{"period":"ytd","weight":-0.195}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1193}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.051908},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.048958},{"month":3,"riseRate":0.111111,"avgChangeRate":-0.056668},{"month":4,"riseRate":0.555556,"avgChangeRate":0.013671},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045608},{"month":6,"riseRate":0.555556,"avgChangeRate":0.069919},{"month":7,"riseRate":0.444444,"avgChangeRate":0.238637},{"month":8,"riseRate":0.777778,"avgChangeRate":0.220515},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.047508},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.024012},{"month":11,"riseRate":0.777778,"avgChangeRate":0.136999},{"month":12,"riseRate":0.555556,"avgChangeRate":0.041318}],"exchange":"NASDAQ","name":"Rhythm Pharmaceuticals Inc.","nameEN":"Rhythm Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rhythm Pharmaceuticals Inc.(RYTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rhythm Pharmaceuticals Inc.,RYTM,Rhythm Pharmaceuticals Inc.股票,Rhythm Pharmaceuticals Inc.股票老虎,Rhythm Pharmaceuticals Inc.股票老虎国际,Rhythm Pharmaceuticals Inc.行情,Rhythm Pharmaceuticals Inc.股票行情,Rhythm Pharmaceuticals Inc.股价,Rhythm Pharmaceuticals Inc.股市,Rhythm Pharmaceuticals Inc.股票价格,Rhythm Pharmaceuticals Inc.股票交易,Rhythm Pharmaceuticals Inc.股票购买,Rhythm Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rhythm Pharmaceuticals Inc.(RYTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}